Quarterly ResultMay 7, 2026, 07:37 AM
ImmunityBio Q1 Revenue Jumps 168% to $44.2M; Cash $380.9M
AI Summary
ImmunityBio reported record first-quarter 2026 financial results, with net product revenue increasing 168% year-over-year to $44.2 million, driven by strong ANKTIVA sales momentum. The company ended the quarter with a robust cash position of $380.9 million. Operational highlights include ANKTIVA's expanded regulatory approvals across 34 countries, full enrollment of its pivotal BCG-naïve NMIBC trial, and updated NCCN guideline recommendations for ANKTIVA plus BCG. While the GAAP net loss was $632.8 million, this was largely due to non-cash fair value changes related to an increase in common stock price.
Key Highlights
- Net product revenue increased 168% year-over-year to $44.2 million in Q1 2026.
- ANKTIVA unit sales volume saw a 168% increase in Q1 2026 compared to Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $380.9 million as of March 31, 2026.
- ANKTIVA is now approved or authorized in five regulatory jurisdictions, covering approximately 34 countries.
- Pivotal BCG-naïve CIS trial (QUILT-2.005) is fully enrolled, with sBLA submission on track for 2026.
- NCCN Clinical Practice Guidelines updated to include ANKTIVA plus BCG for BCG-unresponsive NMIBC with papillary-only disease.
- GAAP net loss attributable to common stockholders was $632.8 million, primarily due to non-cash fair value changes.
- Adjusted net loss attributable to common stockholders increased to $86.2 million in Q1 2026.